China has become one of the world’s busiest hubs for cell and gene therapy research. From CAR-T treatments for blood cancers to base-editing programs targeting inherited blood disorders, the country’s clinical pipeline has expanded fast. But for international patients looking at treatment options in China, one distinction matters more than anything else: whether a therapy is commercially available, only accessible through a formal clinical trial, or still in an early experimental phase.
Here’s a grounded look at the current landscape, based on verified clinical data, regulatory frameworks, and hospital capabilities as of mid-2026.
Gene Editing and Stem Cell Therapy Are Not the Same Thing
These two fields are closely linked, but they solve different problems.
Gene editing uses tools such as CRISPR-Cas9 or base editing to modify a patient’s DNA and correct disease-causing mutations. Stem cell therapy, by contrast, relies on regenerative cells to repair or replace damaged tissue. In some of the most advanced programs, the two approaches are combined: doctors collect a patient’s own stem cells, edit them in a lab, and then reinfuse them to treat a genetic disorder.
Ex vivo vs. in vivo
Most current therapies in China follow an ex vivo model. Cells are removed from the patient, edited in a specialized facility, and then returned after the patient undergoes conditioning chemotherapy. That’s the standard approach in therapies for β-thalassemia and sickle cell disease.
An in vivo model is also starting to enter clinical trials. Instead of removing cells, doctors deliver gene-editing tools directly into the body through intravenous infusion. That could eventually eliminate the need for cell extraction and chemotherapy conditioning, potentially making treatment safer and easier to access.
Base editing vs. traditional CRISPR
Traditional CRISPR-Cas9 cuts both strands of DNA, which can introduce risks such as chromosomal rearrangements or large deletions. Base editing, a newer approach developed by Chinese research teams, changes individual DNA letters without cutting the double helix. That added precision may reduce off-target effects, and early clinical data has been encouraging.
Where the Technology Is Furthest Along
β-Thalassemia and sickle cell disease
The most advanced gene-editing stem cell work in China is aimed at transfusion-dependent β-thalassemia (TDT), a severe inherited blood disorder that typically requires lifelong transfusions.
CS-101
CS-101, developed by CorrectSequence Therapeutics in collaboration with ShanghaiTech University and the First Affiliated Hospital of Guangxi Medical University, uses a "transformer base editor" (tBE) to reactivate fetal hemoglobin production in a patient’s own blood stem cells.
In a Phase 1 trial published in Nature in 2026, five patients achieved transfusion independence within a median of 18 days after infusion. Over a median follow-up of 23 months, all patients maintained stable hemoglobin levels without needing red blood cell transfusions, and no off-target edits or therapy-related serious adverse events were reported. The first treated patient has remained transfusion-free for more than 28 months.
As of mid-2026, CS-101 has completed Phase 1 trials and has been used to treat about 20 patients with β-thalassemia or sickle cell disease, including international patients from Laos and Pakistan. Phase 2/3 trials are now underway.
BRL-101
BRL-101, developed by Boyang Bio and tested at Xiangya Hospital, uses CRISPR-Cas9 to edit the BCL11A enhancer region in patient stem cells. In an early clinical trial, six pediatric patients — including four with the severe β0/β0 genotype — achieved transfusion independence after treatment.
The headline here is significant, but it also comes with an important caveat: these programs remain in clinical development. Transfusion independence is a major milestone, but long-term durability and safety still need further follow-up.
Blood cancers
This is the area where China already has fully commercialized cell therapy.
Unlike gene-editing treatments for inherited diseases, CAR-T therapy for blood cancers is commercially available in China. As of July 2026, the National Medical Products Administration (NMPA) has approved nine CAR-T products covering lymphoma, leukemia, multiple myeloma, and, notably, gastric cancer. That last approval is particularly notable because satri-cel, approved in June 2026, became the world’s first approved solid-tumor CAR-T.
These approved products are delivered at designated tertiary hospitals. Treatment costs typically range from about $120,000 to $215,000 USD, which is still substantially lower than comparable therapies in many Western markets. International patients can access them through standard clinical pathways, though that generally requires a medical visa and a pre-treatment evaluation.
Parkinson’s disease
Shanghai East Hospital, affiliated with Tongji University, has launched China’s first clinical trial using induced pluripotent stem cells (iPSCs) for Parkinson’s disease.
The treatment involves reprogramming a patient’s own cells into stem cells, differentiating them into dopamine-producing neurons, and transplanting those cells into the brain. Twelve-month results announced in early 2025 showed improvements in motor function and quality of life among participants.
Still, this remains an early-phase investigator-initiated trial rather than an approved therapy. More data is needed before anyone can draw conclusions about long-term safety or effectiveness.
Diabetes
In Hainan Province, the Boao Lecheng International Medical Tourism Pilot Zone offers regulated access to mesenchymal stem cell (MSC) therapy for Type 2 diabetes.
These therapies use allogeneic umbilical cord-derived stem cells to modulate inflammation and support pancreatic beta-cell function. This is not gene-editing therapy. It is a regenerative medicine approach offered under special-zone rules.
Published studies suggest that some patients reduce medication needs or improve glycemic control, but outcomes vary, and durability beyond 3–5 years has not been established. Treatment typically costs between $15,000 and $35,000 USD.
The Hospitals Driving This Work
A relatively small group of top-tier institutions is doing much of the serious clinical work in this space.
First Affiliated Hospital of Guangxi Medical University, Nanning
This hospital is a national center for thalassemia treatment, with more than 1,200 bone marrow transplants performed. It is also the lead clinical site for CS-101 base-editing trials and has extensive experience in hematopoietic stem cell transplantation for genetic blood disorders.
Peking University People’s Hospital, Beijing
One of China’s leading centers for hematology and CAR-T therapy, with deep expertise in leukemia, lymphoma, and bone marrow transplantation.
Ruijin Hospital / Shanghai Jiao Tong University School of Medicine, Shanghai
A major center for blood diseases and CAR-T therapy. Its Hainan Boao campus, Ruijin Hainan Hospital, also offers stem cell therapies within the special medical tourism zone.
Shanghai East Hospital, Shanghai
Affiliated with Tongji University, this hospital is conducting early-phase iPSC trials for Parkinson’s disease and other neurological disorders.
Children’s Hospital of Fudan University, Shanghai
A national pediatric medical center with a dedicated rare-disease research ward. It has treated international patients with severe β-thalassemia using CS-101 base-editing therapy and runs trials for spinal muscular atrophy, Fabry disease, and other rare genetic conditions.
West China Hospital, Sichuan University, Chengdu
In 2016, this hospital carried out the world’s first human clinical trial of CRISPR-edited T-cells for advanced lung cancer. It remains active in gene-editing and immuno-oncology research.
Chinese Academy of Medical Sciences Blood Disease Hospital, Tianjin
A specialized national hematology center with strong programs in stem cell transplantation and blood cancer treatment.
The Big Regulatory Shift: Order 818
A major policy change landed on May 1, 2026, when China’s State Council Order No. 818 — officially titled the Regulations on the Administration of Clinical Research and Clinical Translation and Application of Biomedical New Technologies — took effect.
This is China’s first national administrative regulation specifically focused on cell therapy, gene editing, and other advanced biomedical technologies.
What it means for patients
- A dual-track system: Therapies can now move through either the traditional NMPA drug registration route for broad commercial products, or a "technology translation" pathway that lets qualified Grade 3A hospitals offer certain personalized therapies after clinical research and ethics review.
- Hospital-only access: Clinical translation is limited to top-tier tertiary hospitals with accredited ethics committees and specialized facilities.
- No charging during research: Patients cannot be charged for the experimental therapy itself during clinical trials or investigator-initiated trials. Costs may only apply after a therapy receives clinical translation approval.
- Stronger enforcement: Unauthorized use of unproven therapies now carries heavy fines, reinforcing the need to stick with legitimate institutions.
The goal is clear: speed up access to genuine breakthroughs while shutting down the kind of loosely regulated stem cell clinics that operated in gray areas for years.
What International Patients Should Actually Watch For
The most important takeaway is also the simplest one: most gene-editing stem cell therapies in China are still not commercially approved.
Outside of CAR-T and some stem cell products in Hainan Boao, most gene-editing options remain trial-based. That means access is usually tied to enrollment criteria, not direct consumer choice.
Don’t confuse “transfusion independence” with “cure”
The early thalassemia results are genuinely promising. But data beyond 2–3 years is still limited. For now, these therapies are best understood as potentially curative, not definitively proven cures.
Avoid unregulated clinics
Even with tighter oversight, some private clinics may still market unproven stem cell interventions for anti-aging, diabetes, or neurological diseases without proper trial registration. Any patient considering treatment should verify that it is being offered through a Grade 3A public hospital with ethics approval and a legitimate clinical trial registration, including listings on ClinicalTrials.gov or the China Clinical Trial Registry.
Costs and logistics
Here’s the practical cost picture based on currently available options:
- Commercial CAR-T: $120,000–$215,000 USD
- MSC stem cell therapy in Boao Lecheng: $15,000–$35,000 USD
- Clinical trial therapies: often no treatment cost, though travel, accommodation, and pre-treatment workup still apply
Medical visas, typically the S2 category, require official invitation letters from the hospital.
Language and care coordination
Major hospitals in Beijing, Shanghai, and other top-tier cities increasingly have international departments and some English-speaking staff. But in practice, navigating consultations, translating records, and coordinating follow-up care often requires professional support.
The Bottom Line
China’s gene-editing and stem cell sector has moved well beyond basic research and into real clinical innovation. The clearest example is β-thalassemia, where base-editing programs have already produced internationally recognized results. At the same time, the regulatory picture has become more structured under Order 818, creating clearer channels for legitimate therapies while making it harder for unproven operators to function.
For international patients, expectations need to stay aligned with reality. CAR-T is commercially available and established. Gene-editing treatments for inherited blood disorders are in advanced clinical trials with strong early data. Most other applications — including Parkinson’s disease, diabetes, and anti-aging — either remain experimental or rely on conventional stem cell approaches rather than gene editing.
The safest path is straightforward: contact the international departments at major tertiary hospitals, confirm whether your condition matches an approved indication or an open clinical trial, and make sure any treatment is delivered under proper regulatory oversight.
This article is intended for informational purposes only and does not constitute medical advice. Treatment decisions should always be made in consultation with qualified healthcare professionals. Clinical trial availability and eligibility criteria can change frequently, so patients should verify current status directly with hospitals or official registries.